Logo

Your free order overview

You currently have not items to display
Logo

Your contact details

This is a required field

Logo

Thank you!

Thank you for choosing Janssen Medical Cloud for ordering your materials.

/
Bénéfices chez les patients à haut risque de progression

Bénéfices chez les patients à haut risque de progression

Imbruvica, un bénéfice sur la PFS chez les patients à haut risque de progression1</sup

graph-tn-2
smpc-1-tn
RÉFÉRENCES:
1.EHA 2019; RESONATE-2 CLL/SLL; Tedeschi et al.
2. DOF-IBR-Global Numbers-EMEA-SR-0731
IMBRUVICA logo

CP-147123

Logo
This site is published by ©Johnson & Johnson Innovative Medicine NV which is solely responsible for its content. It is intended for European, Middle Eastern and African Healthcare professionals.
Johnson & Johnson Pharmaceutica NV
Legal NoticePolitique de confidentialitéMentions légalesPolitique in matiere de cookies
Cookie Settings